about
Proceedings of Réanimation 2017, the French Intensive Care Society International CongressThrombocytopenia in sarcoidosis.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012.Aldehyde dehydrogenase activity identifies a population of human skeletal muscle cells with high myogenic capacitiesPhase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro.Chronic myeloid leukemia as a secondary neoplasm after anti-cancer radiotherapy: a report of three cases and a brief review of the literature.Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patientsIdentification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis.TNF alpha antagonist therapy and safety monitoring.Abatacept therapy and safety management.Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies.Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3AGalectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell.Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation.Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy.Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction.Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders.Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients.Prospective flow cytometric evaluation of nucleated red blood cells in cord blood units and relationship with nucleated and CD34(+) cell quantification.IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.Impact of MICA and NKG2D polymorphisms in HLA-fully matched related and unrelated hematopoietic stem cell transplantation.Influence of bone marrow nucleated red blood cell dose on outcome after allogeneic haematopoietic stem cell transplantation.Quantification of nucleated red blood cells in allogeneic marrow graft and impact of processing on recovery.ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery.Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.Toll-like receptor 3 regulates cord blood-derived endothelial cell function in vitro and in vivo.
P50
Q28564101-6BF15B7F-A537-413D-8660-61EC61B6D6FAQ33377555-1982735A-587C-4301-96BB-4C4D703D8051Q33400617-B14CC9DC-FC45-4B7D-BE65-B292CFDF5019Q33404104-D40CD632-6E1A-4ABF-88DB-3F7D847747AAQ33406035-5EAB7AB6-ACB8-4A5B-A412-6E95C58B7C78Q33421585-F9514AEA-E303-4170-9EBD-F8005825A426Q33713162-B74EDC85-DD7A-4A75-8B1F-4F73AA174AB4Q33741025-A0099F50-6AE4-4251-BD45-3E6528E6F0C1Q33760295-31277970-330F-40F3-9ADF-C4A94DD0B2ADQ34052050-98FE7A46-3536-4CC6-AF0A-6490DA4B5551Q34549132-BEEBB76E-E754-46D9-A571-269646CF2FBAQ34653811-2894D9F4-D46D-452B-94D0-CE1CD9A8F2A1Q34767237-8AEC6132-8999-43BE-9F51-DFDDB6809413Q34804866-4AB75DC3-EEFB-4E38-92E9-1A799C56027EQ34919711-AAF4487A-7581-4856-9314-1EFDFD25C22BQ35077803-D8AF7ECB-D25E-40CC-BED9-6A884AD045B9Q37635190-E3300E75-7C75-43EA-9B75-4684AD8FE5E7Q37894193-467DBBDB-0BAC-48C0-BD35-C9D1ED621D87Q38006176-01EC383D-8600-4D4C-80B9-B57BD31AB620Q38076576-F3D0221D-0ED0-4B15-8A7C-C633E7AD1201Q40531691-56ADE92A-AE6F-483F-A69B-3E2273742E53Q40900632-40D5CEB6-0494-431A-842D-3D5E5CE45E24Q40971388-4B73D184-4896-4CAC-A1D1-545641D1D3DEQ41721568-285F96C5-35B8-480A-AA9F-C777D1BD8360Q42128667-497FA9ED-7145-4FFE-AFBB-27F49CDF91E5Q43249326-CB47671B-A9C6-46CE-9C38-BC92DDBA5189Q43945175-90EB34FA-BDE2-4952-8CC1-357FBCCF052AQ44313167-5EC60708-88B5-40A4-8F38-BCDEF07EDD1FQ44392643-3336EDA7-0FA8-441F-A3E1-176EA9695453Q45407524-7B4DD581-034C-4FDE-953A-B63805CA77B3Q46080498-378F71E7-273F-4E39-BFED-290942B645E7Q46988007-57555C0A-3E4E-4095-BD47-0F76963B7AD7Q47644573-22C1F004-FE2D-4165-AF4A-7ABECA213A6DQ48231285-FEEFC9CA-8987-4F09-B00C-5695475D2C58Q49595021-0C91B5E7-0331-4919-B1F8-5161D4BDA9B1Q50658141-5589C3B5-DF50-492E-BC05-EC2D7EB48922Q50705083-EF24FAC8-64CD-4629-82A1-630CED1B3C5FQ50740096-027FA1AC-3CE3-4DC5-873E-7F0D8C47FB02Q50881007-33E16586-8503-4B51-B234-6DFCE4B9EDCFQ50924641-D801A66E-13B0-443B-8EDA-95306E109EFD
P50
name
Jean-Pierre Marolleau
@ast
Jean-Pierre Marolleau
@en
Jean-Pierre Marolleau
@es
Jean-Pierre Marolleau
@fr
Jean-Pierre Marolleau
@nl
type
label
Jean-Pierre Marolleau
@ast
Jean-Pierre Marolleau
@en
Jean-Pierre Marolleau
@es
Jean-Pierre Marolleau
@fr
Jean-Pierre Marolleau
@nl
prefLabel
Jean-Pierre Marolleau
@ast
Jean-Pierre Marolleau
@en
Jean-Pierre Marolleau
@es
Jean-Pierre Marolleau
@fr
Jean-Pierre Marolleau
@nl
P214
P269
P2038
Jean-Pierre_Marolleau
P21
P213
0000 0003 5802 8279
P214
P269
P31
P735
P7859
viaf-202018743